on CELSET INC
CELSET INC Introduces SOLTOX to International Markets
CELSET INC., a Korean biotechnology firm specializing in medical aesthetics, has launched SOLTOX, a botulinum toxin type A brand. This marks a significant entry of a Korean botulinum toxin into the international medical aesthetics industry.
SOLTOX is available in 100 and 200 Unit formulations, characterized by its 900 kDa toxin complex, freeze-dried form, and an advanced purification process. This reflects a focus on pharmaceutical quality and controlled manufacturing processes.
The product emphasizes technical specifics without asserting unverified claims on clinical outcomes. SOLTOX is provided as a lyophilized powder for reconstitution by licensed professionals according to local regulations.
The launch is part of CELSET's strategy to enhance its international presence, highlighting Korean biotechnology and adhering to country-specific regulatory standards. SOLTOX expands CELSET's portfolio while ensuring clear information dissemination to healthcare professionals.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all CELSET INC news